The Theseus team is actively exploring additional opportunities to leverage our pan-variant targeted therapy approach to address treatment-resistant cancers.

Our structure-guided drug design approach, integrated with our predictive resistance assay (PRA), allows us to efficiently design and validate small molecule tyrosine kinase inhibitors (TKIs) that successfully inhibit their targets despite the presence of any major cancer-causing and resistance mutations. We are currently evaluating several potential oncogene targets for a next-generation inhibitor against an area of unmet clinical need.

We intend to nominate a third target and expand our pipeline by the end of 2022.